---
title: 'Efficacy and Safety of Daratumumab in Intermediate/High-risk Smoldering Multiple
  Myeloma: Final Analysis of CENTAURUS'
date: '2024-12-09'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/39652826/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&fc=20220326224207&ff=20241209184155&v=2.18.0.post9+e462414
source: heidelberg[Affiliation]
description: Early intervention of smoldering multiple myeloma (SMM) may delay progression
  to multiple myeloma. Here, we present the final analysis of the phase 2 CENTAURUS
  study (NCT02316106). In total, 123 patients with intermediate/high-risk SMM were
  randomized to intravenous daratumumab 16 mg/kg following a Long intense (n = 41),
  Intermediate (n = 41), or Short intense (n = 41) dosing schedule. At a combined
  median follow-up of 85.2 months, in the Long intense, Intermediate, and Short intense
  ...
disable_comments: true
---
Early intervention of smoldering multiple myeloma (SMM) may delay progression to multiple myeloma. Here, we present the final analysis of the phase 2 CENTAURUS study (NCT02316106). In total, 123 patients with intermediate/high-risk SMM were randomized to intravenous daratumumab 16 mg/kg following a Long intense (n = 41), Intermediate (n = 41), or Short intense (n = 41) dosing schedule. At a combined median follow-up of 85.2 months, in the Long intense, Intermediate, and Short intense ...